Simultaneous determination of 4F-MDMB BINACA, a new synthetic cannabinoid, and its metabolites in human blood samples by LC-MS/MS

Year 2020, Volume: 7 Issue: 3, 827 - 832, 30.10.2020

Oya Yeter

https://doi.org/10.18596/jotcsa.770427

Cited By: 4

Abstract

Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamide)-3,3-dimethylbutanoate) also referred to as 4F-MDMB BINACA(M0), is a recently introduced synthetic cannabinoid (SC) that was identified in herbal blends submitted to the Istanbul Narcotics Laboratory of Council of Forensic Medicine (CFM), in March 2019. A sensitive analytical method was developed to be able to detect and quantitate 4F-MDMB BINACA(M0) and its two metabolites, 4F-MDMB BINACA {3,3-dimethylbutanoic acid ((S)-2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3, 3-dimethylbutanoic acid)} (M1), and 4F-MDMB BINACA-N-4-hyroxybutyl (methyl (S)-2-(1-(4-hydroxybutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) (M2) in blood samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The samples were prepared using a solid-phase extraction method. The method validation was performed in terms of linearities, limits of detection (LODs), limits of quantification (LOQs), recoveries, matrix effects, process efficiencies, accuracies, and precisions, was also applied to six blood samples from cases of autopsy in the CFM, Istanbul.

Keywords

Synthetic cannabinoid, 4F-MDMB BINACA, forensic toxicology, drugs of abuse

References

• 1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Perspectives on Drug: Synthetic Cannabinoids in Europe, (2017) . Available at https://www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_0.pdf (Accessed 20 June 2020)
• 2. Schaefer N, Peters B, Bregel D, Kneisel S, Schmidt PH, Ewald AH. A fatal case involving several synthetic cannabinoids. Toxichem Krimtech. 2013;80(Special Issue):248
• 3. Cooper ZD. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. Curr Psychiatry Rep. 2016;18(5):52. doi:10.1007/s11920-016-0694-1
• 4. Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int. 2016;261:e5-10. https://doi.org/10.1016/j.forsciint.2016.02.024
• 5. Giorgetti A, Mogler L, Halter S, Haschimi B, Alt A, Rentsch D. Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE. Forensic Toxicol. 2020;38(2):314-26. https://doi.org/10.1007/s11419-019-00514-w
• 6. Dogan H, Ozucelik D, Aciksari K, Avci A, Yazicioglu M, Celikmen M. New synthetic cannabinoid intoxications in emergency department (It’s grass, Its no sin). Anatol J Psychiatry. 2016;17(1):18-25.
• 7. Lovett C, Wood DM, Dargan PI. Pharmacology and toxicology of the synthetic cannabinoid receptor agonists. Réanimation. 2015;24(5):527-41. DOI 10.1007/s13546-015-1104-4
• 8. Giorgetti A, Busardò FP, Tittarelli R, Auwärter V, Giorgetti R. Post-Mortem Toxicology: A Systematic Review of Death Cases Involving Synthetic Cannabinoid Receptor Agonists. Front Psychiatry. (Accessed 20 Hune 2020) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261860/
• 9. Kronstrand R, Roman M, Andersson M, Eklund A. Toxicological Findings of Synthetic Cannabinoids in Recreational Users. J Anal Toxicol. 2013;37(8):534-41. doi:10.1093/jat/bkt068
• 10. Assi S, Marshall D, Bersani F, Corazza O. Uses, Effects and Toxicity of Synthetic Cannabinoids from the Perspective of People with Lived Experiences. J Psychoactive Drugs. 2020; doi:10.1080/02791072.2020.1723748
• 11. European Monitoring Centre for Drugs and Drug Addiction. European information system and database on new drugs, early warning system reports. Available at https://ednd.emcdda.europa.eu. (Accessed May 20, 2020)
• 12. World Health Organisation (WHO).Critical review report: 4F-MDMB BINACA. 2019. Genava Available at https://www.who.int/medicines/access/controlled-substances/Final_4F-MDMB-BINACA.PDF?ua=1 (Accessed May 25, 2020)
• 13. Krotulski AJ, Mohr ALA, Kacinko SL, Fogarty MF, Shuda SA, Diamond FX.4F-MDMB BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework. J Forensic Sci. 2019;64(5):1451-61.
• 14. Haschimi, B, Mogler, L, Halter, S, Giorgetti, A, Schwarze, B, Westphal, F, Fischman, S, Auwarter, V. Detection of the recently emerged synthetic cannabinoid 4F-MDMB BINACA in “legal high” products and human urine specimens. Drug Test Anal. 2019; 11: 1377– 86. https://doi.org/10.1002/dta.2666
• 15. Scientific Working Group for Forensic Toxicology (SWGTOX) Standard Practices for Method Validation in Forensic Toxicology. J Anal Toxicol. 01 Eylül 2013;37(7):452-74.
• 16. Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. Ocak 2007;165(2-3):216-24.
• 17. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 01 Temmuz 2003;75(13):3019-30.